{"Title": ["FibroGen (FGEN) Shares Cross Above 200 DMA", "Health Care Sector Update for 06/12/2020: GLYC,FGEN,VIE,NVCN", "Health Care Sector Update for 06/12/2020: FGEN,VIE,NVCN", "Friday 6/12 Insider Buying Report: FGEN, KZR", "FibroGen Reports Enrollment In Pamrevlumab Trial In Italy - Quick Facts", "EMA Accepts Astellas' Marketing Authorization Application For Roxadustat", "First Week of FGEN July 17th Options Trading", "FibroGen Inc (FGEN) Q1 2020 Earnings Call Transcript", "FibroGen (FGEN) Shares Cross Above 200 DMA", "FibroGen (FGEN) Shares Cross Above 200 DMA", "How The Pieces Add Up: IYH Targets $234", "FibroGen Inc (FGEN) Q4 2019 Earnings Call Transcript", "FibroGen's Anemia Drug Goes to FDA for Review", "Notable Thursday Option Activity: FGEN, BMRN, ESTC", "FibroGen Appoints Enrique Conterno as Its New CEO", "FibroGen (FGEN) Shares Cross Below 200 DMA", "First Week of December 18th Options Trading For FibroGen (FGEN)", "Analysts Expect 17% Gains Ahead For FBT", "Bullish Two Hundred Day Moving Average Cross - FGEN", "FibroGen Inc (FGEN) Q3 2019 Earnings Call Transcript", "Here\u2019s Why FibroGen\u2019s Stock Popped Friday", "AstraZeneca: Roxadustat Phase III Pooled Analyses Show Positive Efficacy", "FDA Says \"Not Now AVEO\", HALO Axes 160 Jobs, RDHL Gets Nod For H.pylori Drug", "Oversold Conditions For FibroGen (FGEN)", "First Week of FGEN February 2020 Options Trading", "Interesting FGEN Put And Call Options For October 18th", "Analysts Predict 13% Upside For The Holdings of RXL", "FibroGen Inc (FGEN) Q2 2019 Earnings Call Transcript", "FibroGen (FGEN) Shares Cross Above 200 DMA", "Health Care Sector Update for 07/22/2019: KZIA,DVA,FGEN,DVA,NTEC", "Health Care Sector Update for 07/22/2019: FGEN,DVA,NTEC", "Tuesday's ETF Movers: FBT, XME", "Astellas Pharma, FibroGen Announce Approval Of Evrenzo In Japan - Quick Facts", "Interesting FGEN Put And Call Options For October 18th", "Notable Wednesday Option Activity: FIZZ, LEN, FGEN", "Sum Up The Parts: XBI Could Be Worth $125", "November 15th Options Now Available For FibroGen (FGEN)", "FibroGen Inc (FGEN) Q1 2019 Earnings Call Transcript", "Here's Why FibroGen Fell as Much as 26.6% Today", "FibroGen News: Why FGEN Stock Is Plummeting Today", "Monday's ETF Movers: ILF, FBT", "First Week of January 2021 Options Trading For FibroGen (FGEN)", "Notable Wednesday Option Activity: FIZZ, LEN, FGEN", "Financial Exchange Stock Talk: Joe McCann On FibroGen", "How The Parts Add Up: PBE Targets $69", "Options Traders Expect Huge Moves in FibroGen (FGEN) Stock", "4 Biotech Stocks With Major Catalysts in April", "Biotech Stocks With Major Catalysts in April", "RSI Alert: FibroGen (FGEN) Now Oversold", "FibroGen is Now Oversold (FGEN)", "Financial Exchange Stock Talk: Joe McCann On FibroGen", "Financial Exchange Stock Talk: Joe McCann On FibroGen", "How The Parts Add Up: PBE Targets $69", "Noteworthy Tuesday Option Activity: FGEN, DAKT, GS", "What's in Store for Teladoc's (TDOC) Q4 Earnings?", "Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?", "First Week of May 17th Options Trading For FibroGen", "First Week of FGEN February 15th Options Trading", "Health Care Sector Update for 12/20/2018: FGEN,TWST,TLRY,BUD,SPPI", "Health Care Sector Update for 12/19/2018: STRO,CELG,GSK,PFE,FGEN,SURF", "Health Care Sector Update for 12/19/2018: GSK,PFE,FGEN,SURF", "FibroGen is Now Oversold (FGEN)", "FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates", "Cronos (CRON) to Report Q3 Earnings: What's in the Cards?", "Implied IYY Analyst Target Price: $152", "First Week of FGEN February 15th Options Trading", "Health Care Sector Update for 12/20/2018: FGEN,TWST,TLRY,BUD,SPPI", "Health Care Sector Update for 12/19/2018: STRO,CELG,GSK,PFE,FGEN,SURF", "Commit To Buy FibroGen At $45, Earn 12.1% Annualized Using Options", "Analysts Expect FPX Will Reach $80", "Commit To Purchase FibroGen At $48, Earn 13% Annualized Using Options", "Noteworthy Thursday Option Activity: FGEN, BAC, RL", "What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?", "Notable Monday Option Activity: TSLA, FGEN, IBM", "FibroGen Breaks Above 200-Day Moving Average - Bullish for FGEN", "First Week of FGEN November 16th Options Trading", "Commit To Buy FibroGen At $45, Earn 12.1% Annualized Using Options", "Analysts Expect FPX Will Reach $80", "Commit To Purchase FibroGen At $48, Earn 13% Annualized Using Options", "Commit To Buy FibroGen At $40, Earn 13.5% Annualized Using Options", "Noteworthy Thursday Option Activity: AVGO, EXP, FGEN", "How The Pieces Add Up: VTWO Targets $133", "Commit To Buy FibroGen At $40, Earn 15.3% Annualized Using Options", "Implied FBT Analyst Target Price: $151", "Analysts Predict 22% Upside For PBE", "FibroGen is Now Oversold (FGEN)", "Why Ralph Lauren, LendingClub, and FibroGen Jumped Today", "Health Care Sector Update for 08/08/2017: FATE,FGEN,BIOA", "Implied FBT Analyst Target Price: $156", "Why FibroGen Inc Skyrocketed Higher Today", "Health Care Sector Update for 08/08/2017: DEPO,FGEN,BIOA", "Should You Buy FibroGen (FGEN) Ahead of Earnings?", "What's in the Cards for Repros (RPRX) this Earnings Season?", "Should You Sell FibroGen, Inc (FGEN) Before Earnings?", "Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise?", "What's in the Cards for Allergan (AGN) this Earnings Season?", "Why Did FibroGen (FGEN) Stock Hit All-Time High Today?", "Can Ligand (LGND) Spring a Surprise this Earnings Season?", "Is Endo (ENDP) Poised for a Beat This Earnings Season?", "Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?", "Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?", "Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?", "What's in Store for Mallinckrodt (MNK) This Earnings Season?", "What to Expect from Epizyme (EPZM) This Earnings Season?", "Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?", "What's in the Cards for Inovio (INO) This Earnings Season?", "Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?", "What's in the Cards for ACADIA (ACAD) this Earnings Season?", "What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?", "Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings?", "GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?", "Radius Health (RDUS) Q1 Earnings: What's in Store?", "What's in Store for Adverum (ADVM) in Q1 Earnings?", "What's in the Cards for Inovio (INO) This Earnings Season?", "Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?", "What's in the Cards for ACADIA (ACAD) this Earnings Season?", "What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?", "What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?", "What to Expect from Prothena (PRTA) This Earnings Season?", "Commit To Buy FibroGen At $20, Earn 12.8% Annualized Using Options", "What's in Store for Zoetis (ZTS) Stock This Earnings Season?", "After-Hours Earnings Report for March 1, 2017 : AVGO, MNST, OPK, VGR, XON, FSIC, JUNO, ICUI, NKTR, SQM, FGEN, GKOS", "Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%", "FibroGen (FGEN) Shares March Higher, Can It Continue?", "Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.", "Commit To Purchase FibroGen At $10, Earn 10.2% Annualized Using Options", "Why Akebia Therapeutics Inc Stock Zoomed Higher Today", "Health Care Sector Update for 11/09/2016: FGEN,SCMP,CYH", "Why FibroGen Inc Popped Higher Today", "We Did The Math JKK Can Go To $150", "FibroGen (FGEN) Shows Strength: Stock Moves Up 14%", "Commit To Purchase FibroGen At $12.50, Earn 15% Annualized Using Options", "3 Biotech Stocks to Buy in January", "FibroGen is Now Oversold (FGEN)", "Strength Seen in FibroGen (FGEN): Stock Rises 6.3%", "Commit To Purchase FibroGen At $20, Earn 12.4% Annualized Using Options", "FibroGen Becomes Oversold (FGEN)", "Why FibroGen (FGEN) Might Surprise This Earnings Season - Tale of the Tape", "Can Immune Design (IMDZ) Surprise This Earnings Season? - Analyst Blog", "CyberArk Software (CYBR) Q2 Earnings: What's in Store? - Analyst Blog", "FibroGen (FGEN) Looks Good: Stock Moves 8.4% Higher - Tale of the Tape", "FibroGen (FGEN) Shows Strength: Stock Moves Up 5.7% - Tale of the Tape", "Aduro Biotech soars 100% on IPO", "A Biotech Company With One Of The Normal Risks Reduced", "Is FibroGen (FGEN) Stock a Solid Choice Right Now?", "Feeling anemic? Biotech FibroGen prices IPO at $18, toward the top of the range", "Billion dollar biotech: FibroGen sets terms for $124 million IPO", "US IPO Weekly Recap: Virgin America flies high as IPO market reaches 250 with 9 new offerings"], "Elapsed Time": ["JUN 15, 2020", "JUN 12, 2020", "JUN 12, 2020", "JUN 12, 2020", "JUN 8, 2020", "MAY 20, 2020", "MAY 15, 2020", "MAY 9, 2020", "JUN 15, 2020", "APR 24, 2020", "MAR 30, 2020", "MAR 3, 2020", "FEB 12, 2020", "JAN 9, 2020", "JAN 6, 2020", "DEC 30, 2019", "APR 28, 2020", "DEC 26, 2019", "DEC 3, 2019", "NOV 11, 2019", "NOV 11, 2019", "NOV 11, 2019", "NOV 5, 2019", "OCT 2, 2019", "DEC 30, 2019", "AUG 26, 2019", "AUG 19, 2019", "AUG 9, 2019", "AUG 9, 2019", "JUL 22, 2019", "JUL 22, 2019", "JUL 9, 2019", "SEP 20, 2019", "AUG 26, 2019", "JUN 19, 2019", "JUN 17, 2019", "JUN 13, 2019", "MAY 13, 2019", "MAY 10, 2019", "MAY 10, 2019", "JUL 8, 2019", "JUN 26, 2019", "APR 17, 2019", "APR 17, 2019", "APR 15, 2019", "APR 3, 2019", "APR 2, 2019", "APR 2, 2019", "MAY 10, 2019", "APR 17, 2019", "APR 17, 2019", "APR 17, 2019", "FEB 28, 2019", "FEB 26, 2019", "FEB 22, 2019", "FEB 20, 2019", "MAR 21, 2019", "JAN 7, 2019", "DEC 20, 2018", "DEC 19, 2018", "DEC 19, 2018", "NOV 12, 2018", "NOV 8, 2018", "NOV 7, 2018", "FEB 7, 2019", "JAN 7, 2019", "DEC 20, 2018", "OCT 1, 2018", "SEP 28, 2018", "JUL 30, 2018", "JUN 28, 2018", "MAY 10, 2018", "NOV 6, 2018", "OCT 29, 2018", "OCT 17, 2018", "OCT 1, 2018", "SEP 28, 2018", "JUL 30, 2018", "JUN 28, 2018", "NOV 8, 2017", "MAR 15, 2018", "FEB 9, 2018", "FEB 6, 2018", "JAN 8, 2018", "DEC 7, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 8, 2017", "NOV 6, 2017", "AUG 8, 2017", "AUG 8, 2017", "AUG 3, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 4, 2017", "AUG 8, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 4, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 1, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 3, 2017", "MAY 2, 2017", "APR 27, 2017", "APR 26, 2017", "APR 26, 2017", "APR 25, 2017", "MAY 1, 2017", "MAR 1, 2017", "JAN 30, 2017", "JAN 23, 2017", "JAN 5, 2017", "DEC 22, 2016", "DEC 20, 2016", "NOV 9, 2016", "APR 6, 2017", "APR 19, 2016", "FEB 12, 2016", "JAN 27, 2016", "JAN 12, 2016", "JAN 12, 2016", "NOV 18, 2015", "NOV 9, 2015", "NOV 2, 2016", "AUG 10, 2015", "AUG 10, 2015", "AUG 10, 2015", "JUN 22, 2015", "JUN 4, 2015", "APR 15, 2015", "DEC 9, 2014", "SEP 15, 2015", "NOV 13, 2014", "OCT 30, 2014", "NOV 14, 2014"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/fibrogen-fgen-shares-cross-above-200-dma-2020-06-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-12-2020%3A-glycfgenvienvcn-2020-06-12", "https://www.nasdaq.com/articles/health-care-sector-update-for-06-12-2020%3A-fgenvienvcn-2020-06-12", "https://www.nasdaq.com/articles/friday-6-12-insider-buying-report%3A-fgen-kzr-2020-06-12", "https://www.nasdaq.com/articles/fibrogen-reports-enrollment-in-pamrevlumab-trial-in-italy-quick-facts-2020-06-08", "https://www.nasdaq.com/articles/ema-accepts-astellas-marketing-authorization-application-for-roxadustat-2020-05-20", "https://www.nasdaq.com/articles/first-week-of-fgen-july-17th-options-trading-2020-05-15", "https://www.nasdaq.com/articles/fibrogen-inc-fgen-q1-2020-earnings-call-transcript-2020-05-09", "https://www.nasdaq.com/articles/fibrogen-fgen-shares-cross-above-200-dma-2020-06-15", "https://www.nasdaq.com/articles/fibrogen-fgen-shares-cross-above-200-dma-2020-04-24", "https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-iyh-targets-%24234-2020-03-30", "https://www.nasdaq.com/articles/fibrogen-inc-fgen-q4-2019-earnings-call-transcript-2020-03-03", "https://www.nasdaq.com/articles/fibrogens-anemia-drug-goes-to-fda-for-review-2020-02-12", "https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-fgen-bmrn-estc-2020-01-09", "https://www.nasdaq.com/articles/fibrogen-appoints-enrique-conterno-as-its-new-ceo-2020-01-06", "https://www.nasdaq.com/articles/fibrogen-fgen-shares-cross-below-200-dma-2019-12-30", "https://www.nasdaq.com/articles/first-week-of-december-18th-options-trading-for-fibrogen-fgen-2020-04-28", "https://www.nasdaq.com/articles/analysts-expect-17-gains-ahead-for-fbt-2019-12-26", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-fgen-2019-12-03", "https://www.nasdaq.com/articles/fibrogen-inc-fgen-q3-2019-earnings-call-transcript-2019-11-12", "https://www.nasdaq.com/articles/heres-why-fibrogens-stock-popped-friday-2019-11-11", "https://www.nasdaq.com/articles/astrazeneca%3A-roxadustat-phase-iii-pooled-analyses-show-positive-efficacy-2019-11-11", "https://www.nasdaq.com/articles/fda-says-not-now-aveo-halo-axes-160-jobs-rdhl-gets-nod-for-h.pylori-drug-2019-11-05", "https://www.nasdaq.com/articles/oversold-conditions-for-fibrogen-fgen-2019-10-02", "https://www.nasdaq.com/articles/first-week-of-fgen-february-2020-options-trading-2019-12-30", "https://www.nasdaq.com/articles/interesting-fgen-put-and-call-options-for-october-18th-2019-08-26", "https://www.nasdaq.com/articles/analysts-predict-13-upside-for-the-holdings-of-rxl-2019-08-19", "https://www.nasdaq.com/articles/fibrogen-inc-fgen-q2-2019-earnings-call-transcript-2019-08-10", "https://www.nasdaq.com/articles/fibrogen-fgen-shares-cross-above-200-dma-2019-08-09", "https://www.nasdaq.com/articles/health-care-sector-update-for-07-22-2019%3A-kziadvafgendvantec-2019-07-22", "https://www.nasdaq.com/articles/health-care-sector-update-for-07-22-2019%3A-fgendvantec-2019-07-22", "https://www.nasdaq.com/articles/tuesdays-etf-movers%3A-fbt-xme-2019-07-09", "https://www.nasdaq.com/articles/astellas-pharma-fibrogen-announce-approval-of-evrenzo-in-japan-quick-facts-2019-09-20", "https://www.nasdaq.com/articles/interesting-fgen-put-and-call-options-for-october-18th-2019-08-26", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-fizz-len-fgen-2019-06-19", "https://www.nasdaq.com/articles/sum-up-the-parts%3A-xbi-could-be-worth-%24125-2019-06-17", "https://www.nasdaq.com/articles/november-15th-options-now-available-fibrogen-fgen-2019-06-13", "https://www.nasdaq.com/articles/fibrogen-inc-fgen-q1-2019-earnings-call-transcript-2019-05-13", "https://www.nasdaq.com/articles/heres-why-fibrogen-fell-much-26.6-today-2019-05-10", "https://www.nasdaq.com/articles/fibrogen-news%3A-why-fgen-stock-plummeting-today-2019-05-10", "https://www.nasdaq.com/articles/mondays-etf-movers%3A-ilf-fbt-2019-07-08", "https://www.nasdaq.com/articles/first-week-of-january-2021-options-trading-for-fibrogen-fgen-2019-06-26", "https://www.nasdaq.com/articles/financial-exchange-stock-talk-joe-mccann-fibrogen-2019-04-17", "https://www.nasdaq.com/articles/financial-exchange-stock-talk%3A-joe-mccann-fibrogen-2019-04-17", "https://www.nasdaq.com/articles/how-parts-add-pbe-targets-69-2019-04-15", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-fibrogen-fgen-stock-2019-04-03", "https://www.nasdaq.com/articles/4-biotech-stocks-major-catalysts-april-2019-04-02", "https://www.nasdaq.com/articles/biotech-stocks-major-catalysts-april-2019-04-02-0", "https://www.nasdaq.com/articles/rsi-alert%3A-fibrogen-fgen-now-oversold-2019-05-10", "https://www.nasdaq.com/articles/fibrogen-now-oversold-fgen-2019-04-17", "https://www.nasdaq.com/articles/financial-exchange-stock-talk-joe-mccann-fibrogen-2019-04-17", "https://www.nasdaq.com/articles/financial-exchange-stock-talk%3A-joe-mccann-fibrogen-2019-04-17", "https://www.nasdaq.com/articles/health-care-sector-update-02282019-ttoo-celg-bmy-fgen-jnj-pfe-mrk-abt-amgn-2019-02-28", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-fgen-dakt-gs-2019-02-26", "https://www.nasdaq.com/articles/whats-in-store-for-teladocs-tdoc-q4-earnings-2019-02-22", "https://www.nasdaq.com/articles/tenet-healthcare-thc-q4-earnings%3A-whats-in-the-offing-2019-02-20", "https://www.nasdaq.com/articles/first-week-may-17th-options-trading-fibrogen-2019-03-21", "https://www.nasdaq.com/articles/first-week-fgen-february-15th-options-trading-2019-01-07", "https://www.nasdaq.com/articles/health-care-sector-update-12202018-fgentwsttlrybudsppi-2018-12-20", "https://www.nasdaq.com/articles/health-care-sector-update-12192018-strocelggskpfefgensurf-2018-12-19", "https://www.nasdaq.com/articles/health-care-sector-update-12192018-gskpfefgensurf-2018-12-19", "https://www.nasdaq.com/articles/fibrogen-now-oversold-fgen-2018-11-12", "https://www.nasdaq.com/articles/fibrogen-fgen-reports-q3-loss-lags-revenue-estimates-2018-11-08", "https://www.nasdaq.com/articles/cronos-cron-to-report-q3-earnings%3A-whats-in-the-cards-2018-11-07", "https://www.nasdaq.com/articles/implied-iyy-analyst-target-price-152-2019-02-07", "https://www.nasdaq.com/articles/first-week-fgen-february-15th-options-trading-2019-01-07", "https://www.nasdaq.com/articles/health-care-sector-update-12202018-fgentwsttlrybudsppi-2018-12-20", "https://www.nasdaq.com/articles/first-week-fgen-november-16th-options-trading-2018-10-01", "https://www.nasdaq.com/articles/commit-buy-fibrogen-45-earn-121-annualized-using-options-2018-09-28", "https://www.nasdaq.com/articles/analysts-expect-fpx-will-reach-80-2018-07-30", "https://www.nasdaq.com/articles/commit-purchase-fibrogen-48-earn-13-annualized-using-options-2018-06-28", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-fgen-bac-rl-2018-05-10", "https://www.nasdaq.com/articles/whats-in-the-cards-for-biospecifics-bstc-in-q3-earnings-2018-11-06", "https://www.nasdaq.com/articles/notable-monday-option-activity-tsla-fgen-ibm-2018-10-29", "https://www.nasdaq.com/articles/fibrogen-breaks-above-200-day-moving-average-bullish-fgen-2018-10-17", "https://www.nasdaq.com/articles/first-week-fgen-november-16th-options-trading-2018-10-01", "https://www.nasdaq.com/articles/commit-buy-fibrogen-45-earn-121-annualized-using-options-2018-09-28", "https://www.nasdaq.com/articles/analysts-expect-fpx-will-reach-80-2018-07-30", "https://www.nasdaq.com/articles/commit-purchase-fibrogen-48-earn-13-annualized-using-options-2018-06-28", "https://www.nasdaq.com/articles/commit-buy-fibrogen-40-earn-135-annualized-using-options-2017-11-08", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-avgo-exp-fgen-2018-03-15", "https://www.nasdaq.com/articles/how-pieces-add-vtwo-targets-133-2018-02-09", "https://www.nasdaq.com/articles/commit-buy-fibrogen-40-earn-153-annualized-using-options-2018-02-06", "https://www.nasdaq.com/articles/implied-fbt-analyst-target-price-151-2018-01-08", "https://www.nasdaq.com/articles/analysts-predict-22-upside-pbe-2017-12-07", "https://www.nasdaq.com/articles/pre-market-most-active-aug-8-2017-vrx-endp-teva-abb-fgen-qqq-inva-car-kors-nvda-htz-pagp", "https://www.nasdaq.com/articles/why-ralph-lauren-lendingclub-and-fibrogen-jumped-today-2017-08-08", "https://www.nasdaq.com/articles/health-care-sector-update-08082017-fatefgenbioa-2017-08-08", "https://www.nasdaq.com/articles/implied-fbt-analyst-target-price-156-2017-11-06", "https://www.nasdaq.com/articles/why-fibrogen-inc-skyrocketed-higher-today-2017-08-08", "https://www.nasdaq.com/articles/health-care-sector-update-08082017-depofgenbioa-2017-08-08", "https://www.nasdaq.com/articles/should-you-buy-fibrogen-fgen-ahead-of-earnings-2017-08-03", "https://www.nasdaq.com/articles/whats-in-the-cards-for-repros-rprx-this-earnings-season-2017-05-05", "https://www.nasdaq.com/articles/should-you-sell-fibrogen-inc-fgen-before-earnings-2017-05-05", "https://www.nasdaq.com/articles/mylan-myl-q1-earnings%3A-will-the-stock-pull-a-surprise-2017-05-05", "https://www.nasdaq.com/articles/whats-in-the-cards-for-allergan-agn-this-earnings-season-2017-05-04", "https://www.nasdaq.com/articles/why-did-fibrogen-fgen-stock-hit-all-time-high-today-2017-08-08", "https://www.nasdaq.com/articles/can-ligand-lgnd-spring-a-surprise-this-earnings-season-2017-05-04", "https://www.nasdaq.com/articles/is-endo-endp-poised-for-a-beat-this-earnings-season-2017-05-04", "https://www.nasdaq.com/articles/is-horizon-pharma-hznp-poised-for-a-beat-in-q1-earnings-2017-05-04", "https://www.nasdaq.com/articles/puma-biotechnology-pbyi-q1-earnings%3A-stock-to-disappoint-2017-05-03", "https://www.nasdaq.com/articles/jazz-pharma-jazz-q1-earnings%3A-stock-likely-to-disappoint-2017-05-03", "https://www.nasdaq.com/articles/whats-in-store-for-mallinckrodt-mnk-this-earnings-season-2017-05-03", "https://www.nasdaq.com/articles/what-to-expect-from-epizyme-epzm-this-earnings-season-2017-05-03", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-q1-earnings%3A-whats-in-store-2017-05-04", "https://www.nasdaq.com/articles/whats-in-the-cards-for-inovio-ino-this-earnings-season-2017-05-03", "https://www.nasdaq.com/articles/kite-pharma-kite-q1-earnings%3A-is-a-surprise-in-the-cards-2017-05-03", "https://www.nasdaq.com/articles/whats-in-the-cards-for-acadia-acad-this-earnings-season-2017-05-02", "https://www.nasdaq.com/articles/whats-in-store-for-catalyst-cprx-stock-in-q1-earnings-2017-05-02", "https://www.nasdaq.com/articles/will-intrexon-xon-pull-off-a-surprise-in-q1-earnings-2017-05-02", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph-q2-earnings%3A-what-to-expect-2017-05-02", "https://www.nasdaq.com/articles/radius-health-rdus-q1-earnings%3A-whats-in-store-2017-05-01", "https://www.nasdaq.com/articles/whats-in-store-for-adverum-advm-in-q1-earnings-2017-05-03", "https://www.nasdaq.com/articles/whats-in-the-cards-for-inovio-ino-this-earnings-season-2017-05-03", "https://www.nasdaq.com/articles/kite-pharma-kite-q1-earnings%3A-is-a-surprise-in-the-cards-2017-05-03", "https://www.nasdaq.com/articles/whats-in-the-cards-for-acadia-acad-this-earnings-season-2017-05-02", "https://www.nasdaq.com/articles/whats-in-the-cards-for-merrimack-mack-in-q1-earnings-2017-04-27", "https://www.nasdaq.com/articles/what-awaits-aerie-pharmaceuticals-aeri-in-q1-earnings-2017-04-26", "https://www.nasdaq.com/articles/what-to-expect-from-prothena-prta-this-earnings-season-2017-04-26", "https://www.nasdaq.com/articles/commit-buy-fibrogen-20-earn-128-annualized-using-options-2017-04-25", "https://www.nasdaq.com/articles/whats-in-store-for-zoetis-zts-stock-this-earnings-season-2017-05-01", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-1-2017-avgo-mnst-opk-vgr-xon-fsic-juno-icui-nktr-sqm", "https://www.nasdaq.com/articles/aurinia-pharmaceuticals-auph-jumps%3A-stock-rises-5.6-2017-01-30", "https://www.nasdaq.com/articles/fibrogen-fgen-shares-march-higher-can-it-continue-2017-01-23", "https://www.nasdaq.com/articles/better-buy-organovo-holdings-inc-vs-akebia-therapeutics-inc-2017-01-05", "https://www.nasdaq.com/articles/commit-purchase-fibrogen-10-earn-102-annualized-using-options-2016-12-22", "https://www.nasdaq.com/articles/why-akebia-therapeutics-inc-stock-zoomed-higher-today-2016-12-20", "https://www.nasdaq.com/articles/health-care-sector-update-11092016-fgenscmpcyh-2016-11-09", "https://www.nasdaq.com/articles/why-fibrogen-inc-popped-higher-today-2017-04-06", "https://www.nasdaq.com/articles/we-did-math-jkk-can-go-150-2016-04-19", "https://www.nasdaq.com/articles/fibrogen-fgen-shows-strength%3A-stock-moves-up-14-2016-02-12", "https://www.nasdaq.com/articles/commit-purchase-fibrogen-1250-earn-15-annualized-using-options-2016-01-27", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-january-2016-01-12", "https://www.nasdaq.com/articles/fibrogen-now-oversold-fgen-2016-01-12", "https://www.nasdaq.com/articles/strength-seen-in-fibrogen-fgen%3A-stock-rises-6.3-2015-11-18", "https://www.nasdaq.com/articles/commit-purchase-fibrogen-20-earn-124-annualized-using-options-2015-11-09", "https://www.nasdaq.com/articles/fibrogen-becomes-oversold-fgen-2016-11-02", "https://www.nasdaq.com/articles/why-fibrogen-fgen-might-surprise-this-earnings-season-tale-of-the-tape-2015-08-10", "https://www.nasdaq.com/articles/can-immune-design-imdz-surprise-this-earnings-season-analyst-blog-2015-08-10", "https://www.nasdaq.com/articles/cyberark-software-cybr-q2-earnings%3A-whats-in-store-analyst-blog-2015-08-10", "https://www.nasdaq.com/articles/fibrogen-fgen-looks-good%3A-stock-moves-8.4-higher-tale-of-the-tape-2015-06-22", "https://www.nasdaq.com/articles/fibrogen-fgen-shows-strength%3A-stock-moves-up-5.7-tale-of-the-tape-2015-06-04", "https://www.nasdaq.com/articles/aduro-biotech-soars-100-ipo-2015-04-15", "https://www.nasdaq.com/articles/biotech-company-one-normal-risks-reduced-2014-12-09", "https://www.nasdaq.com/articles/is-fibrogen-fgen-stock-a-solid-choice-right-now-2015-09-15", "https://www.nasdaq.com/articles/feeling-anemic-biotech-fibrogen-prices-ipo-18-toward-top-range-2014-11-13", "https://www.nasdaq.com/articles/billion-dollar-biotech-fibrogen-sets-terms-124-million-ipo-2014-10-30", "https://www.nasdaq.com/articles/us-ipo-weekly-recap-virgin-america-flies-high-ipo-market-reaches-250-9-new-offerings-2014"], "Content": []}